Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Histamine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH1 known ✓ | P35367 | 4/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.44 |
| ▸ | HRH4 | Q9H3N8 | 5/20 | 0.41 |
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.41 |
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | MTOR | P42345 | 1/20 | 0.41 |
| ▸ | HRH2 | P25021 | 4/20 | 0.38 |
| ▸ | APEX1 | P27695 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.34 |
| ▸ | MIF | P14174 | 1/20 | 0.34 |
| ▸ | USP2 | O75604 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Histamine SCHEMBL58710 | 1.00 | TDP1 (0.44) | TDP1HRH4HRH3TSHRCYP2C9 | |
| Histamine SCHEMBL887606 | 1.00 | — | — | |
| Histamine SCHEMBL28347218 | 0.98 | TDP1 (0.42) | TDP1HRH4HRH3TSHRCYP2C9 | |
| Histamine SCHEMBL27340939 | 0.98 | — | — | |
| Histamine SCHEMBL1668636 | 0.98 | HRH4 (0.42) | TDP1HRH4HRH3TSHRCYP2C9 | |
| Histamine SCHEMBL2279 | 0.98 | — | — | |
| Histamine SCHEMBL5447892 | 0.98 | — | — | |
| Histamine SCHEMBL289072 | 0.98 | HRH4 (0.42) | TDP1HRH4HRH3TSHRCYP2C9 | |
| Histamine SCHEMBL7444650 | 0.98 | HRH4 (0.42) | TDP1HRH4HRH3TSHRCYP2C9 | |
| Histamine SCHEMBL4760179 | 0.95 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 126 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240377385-A1 | METHODS AND COMPOSITIONS OF MATTER FOR TREATING CANCER AND PREDICTING RESPONSE TO THERAPY | ICCA INC. | 2024-11-14 | — | — | US | disclosed |
| US-20240115678-A1 | PERSONALIZED MULTIDISCIPLINARY CANCER THERAPY | VELTMEYER JAMES (US) | 2024-04-11 | — | — | US | disclosed |
| CN-115047054-B | Dopamine electrochemical microsensor and preparation method and application thereof | 苏州大学 | 2023-07-18 | — | — | CN | disclosed |
| US-20220401541-A1 | INTRATUMORAL ADMINISTRATION OF IMMUNE CELLULAR THERAPEUTICS | FIBROBIOLOGICS, INC. | 2022-12-22 | — | — | US | disclosed |
| EP-4051305-A1 | INTRATUMORAL ADMINISTRATION OF IMMUNE CELLULAR THERAPEUTICS | Figene, LLC (US) | 2022-09-07 | — | — | EP | disclosed |
| US-20210393681-A1 | Treatment of SARS-CoV-2 with Dendritic Cells for Innate and/or Adaptive Immunity | THERAPEUTIC SOLUTIONS INTERNATIONAL, INC. (US) | 2021-12-23 | — | — | US | disclosed |
| WO-2021087439-A1 | INTRATUMORAL ADMINISTRATION OF IMMUNE CELLULAR THERAPEUTICS | FIGENE, LLC (US) | 2021-05-06 | — | — | WO | disclosed |
| US-10716810-B2 | Canine autologous immunotherapy using dendritic cell induced cancer killing immunocytes | Zander Therapeutics, Inc. (US) | 2020-07-21 | — | — | US | disclosed |
| US-20190000879-A1 | CANINE AUTOLOGOUS IMMUNOTHERAPY USING DENDRITIC CELL INDUCED CANCER KILLING IMMUNOCYTES | Zander Therapeutics, Inc. (US) | 2019-01-03 | — | — | US | disclosed |
| US-10030227-B2 | Canine autologous immunotherapy using dendritic cell induced cancer killing immunocytes | ZANDER BIOLOGICS INC. | 2018-07-24 | — | — | US | disclosed |
| US-6180658-B1 | ADMINISTERING 2-METHOXYPHENYL-1-METHYL-5-P-METHYLBENZOYLPYRROLE-2-ACETAMIDEA CETATE | MEDOSAN RICERCA S.R.L. (IT) | 2001-01-30 | — | — | US | disclosed |
| EP-1057814-A1 | TETRAHYDROBENZINDOLE DERIVATIVES | Meiji Seika Kaisha, Ltd. (JP) | 2000-12-06 | — | — | EP | disclosed |
| EP-1024807-A1 | USE OF THE COMPOUND 2-METHOXYPHENYL-1-METHYL-5P-METHYLBENZOYL-PYRROL-2-ACETAMIDO ACETATE FOR THE PRODUCTION OF AN ANTI-INFLAMMATORY DRUG WITH PREVENTION OF GASTRIC HYPERSECRETION AND RENAL IMPAIRMENT | MEDOSAN RICERCA S.r.l. (IT) | 2000-08-09 | — | — | EP | disclosed |
| US-5889041-A | ADMINISTERING AMTOLMETIN GUACIL | MEDOSAN RICERCA S.R.L. (IT) | 1999-03-30 | — | — | US | disclosed |
| WO-1999007363-A1 | USE OF THE COMPOUND 2-METHOXYPHENYL-1-METHYL-5P-METHYLBENZOYL-PYRROL-2-ACETAMIDO ACETATE FOR THE PRODUCTION OF AN ANTI-INFLAMMATORY DRUG WITH PREVENTION OF GASTRIC HYPERSECRETION AND RENAL IMPAIRMENT | MEDOSAN, RICERCA S.R.L. (IT) | 1999-02-18 | — | — | WO | disclosed |
| US-5866600-A | ADMINISTERING AMTOLMETIN GUACYL | MEDOSAN RICERCA S.R.L. (IT) | 1999-02-02 | — | — | US | disclosed |
| EP-0755679-A2 | Use of Amtolmetin Guacil as an anti-inflammatory agent, which also inhibits gastric secretion | MEDOSAN RICERCA S.r.l. (IT) | 1997-01-29 | — | — | EP | disclosed |
| EP-0702685-A1 | TEXAPHYRIN METAL COMPLEX MEDIATED ESTER HYDROLYSIS | THE BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 1996-03-27 | — | — | EP | disclosed |
| WO-1994029316-A2 | TEXAPHYRIN METAL COMPLEX MEDIATED ESTER HYDROLYSIS | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 1994-12-22 | — | — | WO | disclosed |
| US-4211764-A | Gastric secretion stimulation with 2-amino-5-(2-aminoethyl)-1,3,4-thiadiozole | NAUCHNO-ISSLEDOVATELSKY INSTITUT EXPERIMENTALNOI MEDITSINY (SU) | 1980-07-08 | — | — | US | disclosed |